Business Description
NovelStem International Corp
NAICS : 621511
SIC : 8071
ISIN : US4362331005
Description
NovelStem International Corp focuses on the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.02 | |||||
| Equity-to-Asset | -0.87 | |||||
| Debt-to-Equity | -1.83 | |||||
| Debt-to-EBITDA | -0.94 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -187.26 | |||||
| Beneish M-Score | -13.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 30.4 | |||||
| 3-Year FCF Growth Rate | 65.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.14 | |||||
| 9-Day RSI | 27.41 | |||||
| 14-Day RSI | 33.38 | |||||
| 6-1 Month Momentum % | -46.61 | |||||
| 12-1 Month Momentum % | -64.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.25 | |||||
| Quick Ratio | 0.25 | |||||
| Cash Ratio | 0.15 | |||||
| Days Sales Outstanding | 365 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.5 | |||||
| Shareholder Yield % | -80.05 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -24883.33 | |||||
| Net Margin % | -34891.67 | |||||
| FCF Margin % | -2900 | |||||
| ROA % | -192.67 | |||||
| ROIC % | -107.15 | |||||
| ROCE % | -274.22 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.67 | |||||
| EV-to-EBITDA | -1.67 | |||||
| EV-to-Revenue | 527.83 | |||||
| EV-to-FCF | -18.2 | |||||
| Earnings Yield (Greenblatt) % | -59.88 | |||||
| FCF Yield % | -12.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NSTM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NovelStem International Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.012 | ||
| EPS (TTM) ($) | -0.09 | ||
| Beta | 0 | ||
| Volatility % | 69 | ||
| 14-Day RSI | 33.38 | ||
| 14-Day ATR ($) | 0.000478 | ||
| 20-Day SMA ($) | 0.0626 | ||
| 12-1 Month Momentum % | -64.65 | ||
| 52-Week Range ($) | 0.06 - 0.2768 | ||
| Shares Outstanding (Mil) | 46.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NovelStem International Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NovelStem International Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NovelStem International Corp Frequently Asked Questions
What is NovelStem International Corp(NSTM)'s stock price today?
The current price of NSTM is $0.06. The 52 week high of NSTM is $0.28 and 52 week low is $0.06.
When is next earnings date of NovelStem International Corp(NSTM)?
The next earnings date of NovelStem International Corp(NSTM) is .
Does NovelStem International Corp(NSTM) pay dividends? If so, how much?
NovelStem International Corp(NSTM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers